Gradient Investments LLC Has $681,000 Holdings in Celgene Co. (CELG)

Celgene logo Gradient Investments LLC trimmed its position in shares of Celgene Co. (NASDAQ:CELG) by 19.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,629 shares of the biopharmaceutical company’s stock after selling 2,537 shares during the quarter. Gradient Investments LLC’s holdings in Celgene were worth $681,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of CELG. Jennison Associates LLC boosted its holdings in Celgene by 50.2% during the 3rd quarter. Jennison Associates LLC now owns 8,228,124 shares of the biopharmaceutical company’s stock worth $736,335,000 after acquiring an additional 2,748,302 shares during the last quarter. FMR LLC boosted its holdings in Celgene by 26.0% during the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after acquiring an additional 2,119,257 shares during the last quarter. Edgewood Management LLC boosted its holdings in Celgene by 13.2% during the 3rd quarter. Edgewood Management LLC now owns 15,757,525 shares of the biopharmaceutical company’s stock worth $1,410,141,000 after acquiring an additional 1,832,981 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Celgene by 15.3% during the 3rd quarter. Janus Henderson Group PLC now owns 10,461,658 shares of the biopharmaceutical company’s stock worth $936,215,000 after acquiring an additional 1,391,617 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Celgene by 38.8% during the 3rd quarter. AQR Capital Management LLC now owns 4,090,345 shares of the biopharmaceutical company’s stock worth $366,044,000 after acquiring an additional 1,143,027 shares during the last quarter. 72.84% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on CELG shares. Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Cantor Fitzgerald initiated coverage on shares of Celgene in a report on Monday, October 1st. They issued an “overweight” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Thursday, October 11th. BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Finally, Leerink Swann set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Friday, October 26th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $110.47.

Shares of Celgene stock opened at $86.27 on Tuesday. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $106.67. The stock has a market capitalization of $60.32 billion, a P/E ratio of 12.61, a PEG ratio of 0.46 and a beta of 1.44. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. As a group, sell-side analysts forecast that Celgene Co. will post 7.45 EPS for the current year.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. Institutional Ownership by Quarter for Celgene (NASDAQ:CELG) Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *